Citations

Clear

148 citation(s) found for "Stock, W".

CRS/ICANS Prophylaxis does not Improve Outcomes in adult patients with Relapsed/Refractory B-cell acute lymphoblastic leukemia (B-ALL) treated with brexucabtagene autoleucel
McCauley, Ross, Zhang, Amy, Kota, Vamsi, Boccucci, Jacob, Grunwald, Michael, Ulrickson, Matthew, Hill, LaQuisa, Muhsen, Ibrahim, Sasine, Joshua, Advani, Anjali, Aldoss, Ibrahim, Sandhu, Karamjeet, Reshef, Ran, Luskin, Marlise, Lin, Chenyu, Cassaday, Ryan, Kopmar, Noam, Solh, Melhem, Bobillo, Silvina Odstrcil, Tsai, Stephanie, Hilal, Talal, Shah, Bijal, Faramand, Rawan, Park, Jae, Valtis, Yannis, Othman, Tamer, Vasu, Sumithira, Bezerra, Evandro, Leonard, Jessica, Tan, Virginia, O'Dwyer, Kristen, Moore, Jozal, Jamy, Omer, Mohty, Razan, Kumaran, Muthu, Hoeg, Rasmus, Stock, Wendy, Oliai, Caspian, Lill, Georgia, Schwartz, Marc, Koura, Divya, Dykes, Kaitlyn, Logan, Aaron, Daunov, Michael, Byrd, Ken, Yalniz, Fevzi, Frey, Noelle, Connor, Matthew, Yaghmour, George, Gatell, Vivian Irizarry, Jackson, Clayton, Oluwole, Olalekan, Al-Darobi, Ali, Chen, Evan, Lee, Catherine, O'Connor, Timothy, Dholaria, Bhagirathbhai, Bachanova, Veronika, Tracy, Sean, Srinagesh, Hrishikesh, Miller, Katharine, Sutherland, Katherine, Majhail, Navneet, Mountjoy, Luke, Malik, Shahbaz, Ramakrishnan, Aravind, Shaughnessy, Paul, Mathews, John, Wang, Eunice, Battiwalla, Minoo, Roloff, Gregory, Muffly, Lori, Muffly, Lori , Muffly, Lori , McCauley, Ross, Zhang, Amy, Kota, Vamsi, Boccucci, Jacob, Grunwald, Michael, Ulrickson, Matthew, Hill, LaQuisa, Muhsen, Ibrahim, Sasine, Joshua, Advani, Anjali, Aldoss, Ibrahim, Sandhu, Karamjeet, Reshef, Ran, Luskin, Marlise, Lin, Chenyu, Cassaday, Ryan, Kopmar, Noam, Solh, Melhem, Bobillo, Silvina Odstrcil, Tsai, Stephanie, Hilal, Talal, Shah, Bijal, Faramand, Rawan, Park, Jae, Valtis, Yannis, Othman, Tamer, Vasu, Sumithira, Bezerra, Evandro, Leonard, Jessica, Tan, Virginia, O'Dwyer, Kristen, Moore, Jozal, Jamy, Omer, Mohty, Razan , Kumaran, Muthu, Hoeg, Rasmus, Stock, Wendy, Oliai, Caspian, Lill, Georgia, Schwartz, Marc, Koura, Divya, Dykes, Kaitlyn, Logan, Aaron, Daunov, Michael, Byrd, Ken, Yalniz, Fevzi, Frey, Noelle, Connor, Matthew, Yaghmour, George, Gatell, Vivian Irizarry, Jackson, Clayton, Oluwole, Olalekan, Al-Darobi, Ali, Chen, Evan, Lee, Catherine, O'Connor, Timothy, Dholaria, Bhagirathbhai, Bachanova, Veronika, Tracy, Sean, Srinagesh, Hrishikesh, Miller, Katharine, Sutherland, Katherine, Majhail, Navneet, Mountjoy, Luke, Malik, Shahbaz, Ramakrishnan, Aravind, Shaughnessy, Paul, Mathews, John, Wang, Eunice, Battiwalla, Minoo, Roloff, Gregory

Mayo Clinic

Blood | December 4, 2025 | Volume: 146 | Issue: Supplement 1 | Pages: 2396-2396

10.1182/blood-2025-2396 Get It

Abstract Introduction: CD19-directed CAR T-cell (CAR-T) therapy has substantially improved clinical outcomes for adults with relapsed or refractory (R/R) B-cell acute lymphoblastic leukemia (B-ALL). However, notable toxicities are associated with CAR-T, including cytokine release syndrome (CRS) and immune effector cell-associated neurotoxicity syndrome (ICANS). Variable practice patterns have emerged regarding the use of CRS/ICANS prophylaxis (ppx) via corticosteroids and/or other pharmacologic agents, but the utility of these approaches on reducing CRS or ICANS following CAR-T in B-ALL remains unknown. Thus, we utilized the Real-World Outcomes Collaborative for CAR T in ALL (ROCCA) database to evaluate associations between ppx and the development and severity of CRS or ICANS following brexucabtagene autoleucel (brexu-cel) for B-ALL. Methods: Adult patients (pts) who received standard-of-care brexu-cel for relapsed/refractory B-ALL across 40+ US centers were included. Primary endpoints were the incidence of CRS and ICANS within 28 days of CAR-T infusion. Secondary endpoints included timing of CRS and ICANS onset, progression-free survival (PFS) and overall survival (OS). Univariable and multivariable logistic regression evaluated associations between ppx and incidence of CRS/ICANS; KM and log-rank methods were used for survival analyses. Results: A total of 378 pts were included: 53 pts (14.0%) received CRS/ICANS ppx and 325 (86.0%) received no ppx. Ppx agents included steroids only (26.4%), steroid and anakinra (52.8%), anakinra only (15.1%), and steroid and tocilizumab (5.7%). Pts in the ppx group had a higher proportion of Hispanic pts (64% vs 34%), Ph-like (36% vs 19%) and a lower proportion had 0-5% bone marrow blasts at apheresis (38% vs 53%). The ppx and no ppx groups were similar in age, prior therapies, CAR-T indication, and marrow blasts >50%. Cumulative incidence of any grade (gr) CRS was 94% with ppx and 86% with no ppx (p=0.025), of any gr ICANS was 53% with ppx and 51% with no ppx (0= 0.85). Cumulative incidence of gr 3-4 CRS was 9% in the ppx group and 10% in the no ppx group (p=1.00), of gr 3-4 ICANS was 26% in the ppx group and 29% in the no ppx group (p=0.71). Median time to onset for any gr CRS or any gr ICANS was identical in the ppx and no ppx cohorts (CRS: 5 days, range ppx 1-9 days, no ppx 0-14 days; ICANS: 7 days, ppx 1-20 days, no ppx 0-16 days). Univariate logistic regression analyses showed no significant association between ppx and the incidence of gr 2-4 CRS (OR 1.34, 95% CI: 0.75-2.40, p=0.326) or gr 3-4 ICANS (OR 0.88, 95% CI: 0.46-1.70, p=0.708). Multivariate analysis adjusting for ethnicity, leukemia genetic sub-type, and pre-apheresis disease burden similarly found no significant associations between ppx and gr 2-4 CRS (adjusted OR 1.06, 95% CI: 0.55-2.01, p=0.870) or gr 3-4 ICANS (OR 1.23, 95% CI: 0.59-2.55, p=0.584). When comparing steroid-only ppx (N=14) to steroid combinations or other drug ppx (N=39), there was no significant differences in gr 2-4 CRS (57% vs 44%, p=0.345) or gr 3-4 ICANS (43% vs 21%, p=0.115). Comparing cumulative incidence of dexamethasone (dex) exposure, pts in the ppx group had numerically greater dex exposure than pts in the no ppx group, with median (range) dosing of 182 mg (10-1386mg) and 100mg (1-4000mg), respectively. Finally, we found no significant differences in PFS or OS based on ppx. Median PFS was 9.6 months in the ppx group vs 13.3 months in the no ppx group (p=0.646) and median OS was 17.2 months in the ppx group vs 34.4 months in the no ppx group (p=0.170). Conclusions: In this large cohort of adult patients with R/R ALL receiving brexu-cel CAR-T therapy, prophylaxis intended to prevent CRS/ICANS was ineffective at reducing CRS/ICANS incidence, time to onset, or overall steroid exposure. Furthermore, PFS and OS were comparable between patients who received prophylaxis and those who did not. In the absence of prospective trials in B-ALL, these data suggest that current strategies of CRS/ICANS prophylaxis has limited benefit.
KMT2Ar, but not other high-risk genetics, adversely impacts outcomes in adult patients with relapsed/refractory (R/R) Philadelphia chromosome negative B-cell acute lymphoblastic leukemia (B-ALL) treated with brexucabtagene autoleucel (Brexu-cel)
Leonard, Jessica, Ladha, Abdullah, Faramand, Rawan, Roloff, Gregory, Valtis, Yannis, Tan, Virginia, Miller, Katharine, Zhang, Amy, Grunwald, Michael, Kota, Vamsi, Boccucci, Jacob, Ulrickson, Matthew, Al-Darobi, Ali, Hill, LaQuisa, Muhsen, Ibrahim, Sasine, Joshua, Advani, Anjali, Sandhu, Karamjeet, Reshef, Ran, Luskin, Marlise, Chen, Evan, Lin, Chenyu, Cassaday, Ryan, Kopmar, Noam, Solh, Melhem, Lee, Catherine, Bobillo, Silvina Odstrcil, Tsai, Stephanie, O'Connor, Timothy, Hilal, Talal, Park, Jae, Vasu, Sumithira, Bezerra, Evandro, O'Dwyer, Kristen, Moore, Jozal, Wang, Eunice, McCauley, Ross, Majhail, Navneet, Ramakrishnan, Aravind, Mountjoy, Luke, Malik, Shahbaz, Battiwalla, Minoo, Shaughnessy, Paul, Mathews, John, Srinagesh, Hrishikesh, Sutherland, Katherine, Jamy, Omer, Mohty, Razan, Kumaran, Muthu, Hoeg, Rasmus, Oliai, Caspian, Lill, Georgia, Stock, Wendy, Schwartz, Marc, Othman, Tamer, Koura, Divya, Dykes, Kaitlyn, Logan, Aaron, Daunov, Michael, Byrd, Ken, Yalniz, Fevzi, Bachanova, Veronika, Tracy, Sean, Grover, Punita, Connor, Matthew, Yaghmour, George, Gatell, Vivian Irizarry, Jackson, Clayton, Oluwole, Olalekan, Dholaria, Bhagirathbhai, Frey, Noelle, Muffly, Lori, Shah, Bijal, Aldoss, Ibrahim, Muffly, Lori , Muffly, Lori , Leonard, Jessica, Ladha, Abdullah, Faramand, Rawan, Roloff, Gregory, Valtis, Yannis, Tan, Virginia, Miller, Katharine, Zhang, Amy, Grunwald, Michael, Kota, Vamsi, Boccucci, Jacob, Ulrickson, Matthew, Al-Darobi, Ali, Hill, LaQuisa, Muhsen, Ibrahim, Sasine, Joshua, Advani, Anjali, Sandhu, Karamjeet, Reshef, Ran, Luskin, Marlise, Chen, Evan, Lin, Chenyu, Cassaday, Ryan, Kopmar, Noam, Solh, Melhem, Lee, Catherine, Bobillo, Silvina Odstrcil, Tsai, Stephanie, O'Connor, Timothy, Hilal, Talal, Park, Jae, Vasu, Sumithira, Bezerra, Evandro, O'Dwyer, Kristen, Moore, Jozal, Wang, Eunice, McCauley, Ross, Majhail, Navneet, Ramakrishnan, Aravind, Mountjoy, Luke, Malik, Shahbaz, Battiwalla, Minoo, Shaughnessy, Paul, Mathews, John, Srinagesh, Hrishikesh, Sutherland, Katherine, Jamy, Omer, Mohty, Razan , Kumaran, Muthu, Hoeg, Rasmus, Oliai, Caspian, Lill, Georgia, Stock, Wendy, Schwartz, Marc, Othman, Tamer, Koura, Divya, Dykes, Kaitlyn, Logan, Aaron, Daunov, Michael, Byrd, Ken, Yalniz, Fevzi, Bachanova, Veronika, Tracy, Sean, Grover, Punita, Connor, Matthew, Yaghmour, George, Gatell, Vivian Irizarry, Jackson, Clayton, Oluwole, Olalekan, Dholaria, Bhagirathbhai, Frey, Noelle, Shah, Bijal, Aldoss, Ibrahim

Mayo Clinic

Blood | December 4, 2025 | Volume: 146 | Issue: Supplement 1 | Pages: 3365-3365

10.1182/blood-2025-3365 Get It

Abstract Introduction: Brexu-cel is a highly effective treatment for R/R B-ALL, with complete responses achieved in 71% of patients (pts) treated in the pivotal ZUMA-3 trial. Patients with B-ALL with high-risk (HR) genetics are known to have inferior outcomes with chemotherapy, but little is known about the influence of HR ALL genetics on responses to chimeric antigen receptor (CAR)-T in adults. In this study, we assessed the impact of HR ALL genetics on outcomes in a large cohort of adult patients treated with brexu-cel for R/R Philadelphia chromosome (Ph)-negative B-ALL. Methods: Patient characteristics and outcomes were obtained from the Real-World Outcomes Collaborative of CAR-T in Adult ALL (ROCCA) database which includes data from 40 U.S. centers. NCCN guidelines (NCCN Guidelines in Oncology, ALL v2.2025) were used to define HR B-ALL genetics; lack of HR genetics was defined as standard-risk (SR). The primary outcome was event-free survival (EFS), defined as lack of response, disease progression, or death from any cause. Secondary outcomes were overall survival (OS), relapse free survival (RFS) and response rates including complete response (CR), CR incomplete count recovery (CRi), measurable residual disease negative CR (MRD-) by flow or NGS and progressive disease (PD). Multivariable models were adjusted for age, pre-infusion blast percentage, prior allo-HCT, and post CAR-T allo-HCT (modeled as a time-varying covariate). Results: The cohort included 286 pts: 169 with HR and 117 with SR B-ALL. The HR cohort included TP53m (n=24, 14%), KMT2Ar (n=16, 9%), CRLF2r (n=65, 39%) and other HR genetics such as JAK2 and other Ph-like, IKZF1, complex cytogenetics (n=64, 38%). Relative to SR pts, HR pts were more commonly Hispanic (50% vs 28%). HR and SR pts had similar disease burden pre-apheresis (>5% blasts: 58% vs 53%), prior blinatumomab (60% vs 58%), prior inotuzumab (42% vs 46%), and prior allo HCT (27% vs 37%). The presence of CNS disease (11% HR vs 12% SR) and extramedullary disease (EMD, 22% HR vs 29% SR) at apheresis was also similar. CR/CRi was achieved in 90.5% of evaluable HR pts (n=147) and 90.2% of evaluable SR pts (n=102); MRD- rates were also similar between HR and SR pts at 78.9% and 78.2% respectively. In unadjusted analyses, EFS did not significantly differ between HR pts (median 9.6 mos; 1-yr: 46%, 95% CI 38%-54%) and SR pts (median 11.6 mos; 1-yr: 48%, 95% CI 38%- 58%). Median RFS (HR: 12.2 mos, SR: 13.3 mos) and median OS (HR: 22.4 mos, SR: 21.0 mos) were also similar. Multivariable models demonstrated no significant associations between HR B-ALL and EFS (HR 1.09, 95% CI 0.73-1.63), RFS (HR 1.13, 95% CI 0.71-1.80), or OS (HR 0.96, 95% CI 0.62- 1.48) relative to SR ALL. 28% of HR patients and 21% of SR patients underwent consolidative allo-HCT. Among the HR subgroup, CR/CRi rate was lowest in KMT2Ar (71%) relative to TP53m (95%), CRLF2r (95%), and other HR genetics (89%). The median EFS was lowest in KMT2Ar (4.1 mos), followed by TP53m (6.9 mos), CRLF2r (11.6 mos), and other HR (11.1 mos). Median OS was also lowest in KMT2Ar (6.8 mos) vs 22.4 mos in TP53m and not reached in CRLF2r or other HR. PD was highest in KMT2Ar pts (29%), as compared to 11% HR other, 10% SR, and 5% TP53 and CRLF2r. The rate of relapse among those that achieved CR across the groups was similar and ranged between 28% -40%. Rates of CD19 negative relapse were similar between all subgroups (13%-15%), however 21% of KMT2A pts underwent myeloid transformation as compared 0% for TP53 and CRLF2 pts, and 2% among other HR and SR pts. 25% of KMT2Ar patients underwent consolidative allo-HCT as compared to 32% CRLF2 pts, 29% TP53 pts, 25% other HR pts and 21% SR pts. Multivariable models evaluating the different genomic subgroups demonstrated that relative to SR B-ALL, only KMT2Ar was associated with inferior OS (HR 3.17, 95% CI 1.53-6.58, p=0020). No associations were seen between HR subgroups and EFS. Conclusion: To our knowledge, this analysis represents the largest examination of adult B-ALL recipients of CAR-T assessed by genomic risk group. We found that response rates and survival outcomes following brexu-cel were similar among HR and SR B-ALL pts, including pts with TP53m and CRLF2r. However, pts with KMT2Ar had lower response rates and dismal EFS and OS, with higher rates of PD and myeloid transformation at relapse, suggesting that alternative strategies are necessary to improve outcomes for patients with R/R KMT2Ar B-ALL.
Derivation and external validation of a venous thromboembolism risk prediction model in asparaginase-treated ALL
Anderson, Daniela R., Gangaraju, Radhika , Sedhom, Wafik G., Hamulyák, Eva N. , Wang, Tzu‐Fei , O’Dwyer, Kristen M. , Muthiah, Chandrasekar, Liedtke, Michaela , Badar, Talha , Shimony, Shai , Robinson, Renana , Dinner, Shira, Biemond, Bart J. , Goldberg, Leah, Kapadia, Anjani , Levavi, Hannah , Bar‐Natan, Michal , Hyfte, Grace Van , Bansal, Karan, Gerrits, Anke M., Litzow, Mark R. , Luger, Selina M. , Wolach, Ofir , Shomali, William , Stock, W, O'Dwyer, Kristin , Liedtke, Michaela , Badar, Talha , Shimony, Shai , Robinson, Renana , Sanfilippo, Kristen , Derkach, Andriy , Biemond, Bart J , Levavi, Hannah , Carrier, Marc , Fulcher, Jill , Litzow, Mark R. , Luskin, Marlise R , Wolach, Ofir , Shomali, William , Zwicker, Jeffrey I , Carney, Brian J. , Derkach, Andriy , Nemirovsky, David , Carrier, Marc , Murthy, Guru Subramanian Guru , Stock, Wendy, Leader, Avi

Mayo Clinic

Blood Advances | October 31, 2025 | Volume: 10 | Issue: 3 | Pages: 593-603

10.1182/bloodadvances.2025017862 | PMID 41170879 Get It

Abstract The incidence of venous thromboembolism (VTE) in patients with acute lymphoblastic leukemia (ALL) receiving asparaginase-based induction is high despite primary thromboprophylaxis. Our aim was to derive and externally validate a VTE risk prediction model in patients with ALL receiving asparaginase-based induction. We conducted a multicenter retrospective cohort study of patients (aged ≥18 years) with newly diagnosed ALL receiving asparaginase-based induction. The derivation and external validation cohorts included 306 and 94 patients, respectively. Primary outcome was VTE at any site. A cause-specific Cox proportional hazards model stratified by thromboprophylaxis and center was performed to identify VTE risk factors in the derivation cohort. A risk prediction model for VTE at 30 days was derived using variables with P value < .05 in the multivariable model and was tested in the validation cohort. VTE risk factors on multivariable analysis in the derivation cohort included D-dimer ≥1 μg fibrinogen equivalent unit per mL (hazard ratio [HR], 2.64; 95% confidence interval [CI], 1.07-6.5) and hemoglobin (HR for each 1 g/dL increment, 1.19; 95% CI, 1.06-1.34) at ALL diagnosis. A VTE risk score based on these variables distinguished between a 4% (95% CI, 0.72-12) and 20% (95% CI, 14-27) 30-day cumulative incidence of VTE in the derivation cohort, with similar findings in the validation cohort (area under the curve, 0.56). The negative predictive value for VTE at 30 days was 96% and 93% in the derivation and validation cohorts, respectively, and the positive predictive value was 20% in both. We derived and validated a model using D-dimer and hemoglobin, which stratifies VTE risk in patients with ALL receiving asparaginase-based induction.
Feasibility of Symptom Burden Assessments and Early Palliative Care Integration in an Adolescent and Young Adult Leukemia Clinic
Monick, Sarah, Hanson, Collin, Hoehn, K. Sarah , Henderson, Tara O. , Daugherty, Christopher K. , Wang, Amy , Monick, Sarah E, Hlubocky, Fay J. , Stock, Wendy , DuVall, Adam , McNeer, Jennifer L.

Mayo Clinic

Journal of Adolescent and Young Adult Oncology | October 22, 2025 | Volume: 15 | Issue: 5 | Pages: 378-383

10.1177/21565333251389438 | PMID 41122915 Get It

Adolescents and young adults (AYA; ages 15–39) with acute leukemia have significant unmet supportive care needs. This pilot study integrated same-day palliative care (PC) into an AYA leukemia clinic, measuring symptom burden (SB) with validated symptom assessment tools at baseline, 3, and 6 months. Among 31 patients, moderate-severe symptoms included tiredness, anxiety, and poor appetite. AYAs experienced high SB and psychological distress, regardless of care phase or sociodemographics. With PC integration, tiredness and depression improved significantly; no symptoms worsened. Half of the PC visits led to management changes. Early integration of symptom-focused PC was feasible, value-adding, and well-received by patients.
Inotuzumab Ozogamicin Then Blinatumomab for Older Adults With Newly Diagnosed B-Cell ALL: Alliance Study A041703 Cohort 1 Results
Wieduwilt, Matthew J. , Yin, Jun , Kour, Oudom, Teske, Rebecca, Stock, Wendy , Escherich, Carolin S. , Byrd, Kenneth, Doucette, Kimberley , Mangan, James K. , Hall, Scott, Jamieson, Katarzyna , Dinner, Shira, Bseiso, Ali W., Giordano, Giorgia , Saygin, Caner , Litzow, Mark R. , Stone, Richard M. , Escherich, Carolin , Yang, Jun J.J. , Mims, Alice S , Uy, Geoffrey , Litzow, Mark R. , Stone, Richard M , Stock, Wendy , Wieduwilt, Matthew J , Li, Zhenhua , Uy, Geoffrey L.

Mayo Clinic

Journal of Clinical Oncology | September 30, 2025 | Volume: 43 | Issue: 32 | Pages: 3526-3535

10.1200/jco-25-00307 | PMID 41026957 Get It

PURPOSE Older patients with ALL receiving conventional chemotherapy have poor survival due to toxic death and relapse. We hypothesized that a chemotherapy-free, targeted regimen using the anti-CD22 antibody-calicheamicin conjugate inotuzumab ozogamicin followed by the bispecific anti-CD19/CD3 T-cell engager blinatumomab would reduce toxic death and yield high rates of prolonged remission and survival. METHODS Eligible patients were age 60 years and older with untreated, Philadelphia chromosome (Ph)–negative, CD22-positive, B-cell ALL. Patients received up to two cycles of inotuzumab ozogamicin followed by four or five cycles of blinatumomab with intrathecal methotrexate CNS prophylaxis. The primary end point was 1-year event-free survival (EFS). RESULTS The 33 eligible patients had a median age of 71 years (range, 60-84) and a median CD22 expression of 92% (range, 21%-100%). Eight (24%) had previous chemotherapy or radiation for other cancers, six for multiple myeloma. The composite complete remission rate was 85% after two cycles of inotuzumab ozogamicin and 97% by the end of two cycles of blinatumomab. At a median follow-up of 30 months, the 1-year EFS and overall survival were 75% (95% CI, 61 to 92) and 85% (95% CI, 73 to 98), respectively. EFS was shorter with lower CD22 expression or detectable measurable residual disease at any time point. CONCLUSION Inotuzumab ozogamicin then blinatumomab without maintenance chemotherapy in older patients with untreated, Ph-negative, CD22-positive, B-cell ALL yields a high remission rate and excellent EFS. Given the lack of standard, safe, and effective therapies in this population, the regimen should be considered a standard treatment option.
Differentiation-dependent EBF1 activity determines CD22 transcription and leukemia sensitivity to inotuzumab ozogamicin
Escherich, Carolin S. , Li, Zhenhua , Li, Yizhen , Walker, Megan, Yoshimura, Satoshi , Yang, Wenjian , Huang, Xin , Yu, Jiyang , Paietta, Elisabeth , Konopleva, Marina , Jabbour, Elias, Litzow, Mark R. , Inaba, Hiroto , Evans, William E. , Savic, Daniel , Li, Yizhen , Yang, Wenjian , Huang, Xin , Yu, Jiyang , Konopleva, Marina , Litzow, Mark R. , Pui, Ching-Hon , Loh, Mignon L , Inaba, Hiroto , Escherich, Carolin , Barnett, Kelly R. , Stock, Wendy , Kornblau, Steven M. , Jabbour, Elias , Loh, Mignon L. , Yang, Jun

Mayo Clinic

Blood | May 28, 2025 | Volume: 146 | Issue: 4 | Pages: 471-481

10.1182/blood.2024028215 | PMID 40435412 Get It

Abstract Inotuzumab ozogamicin (InO) is an antibody-calicheamicin conjugate with high efficacy in lymphoid malignancies. It targets the B-cell surface protein CD22, which is expressed in most B-cell acute lymphoblastic leukemia (B-ALL) cases, albeit with variable intensity. However, factors governing CD22 expression and thus leukemia sensitivity to InO remain incompletely understood. Using multiomic characterization of 196 human B-ALL samples, coupled with ex vivo InO sensitivity profiling, we showed that early leukemia differentiation arrest at the pre–pro-B stage is associated with resistance to InO. Screening of 1639 transcription factor genes identified early B-cell factor 1 (EBF1) as a key regulator of CD22 expression (false discovery rate of 7.1 × 10−4). When comparing the assay for transposase-accessible chromatin with sequencing profiling results of the most InO-sensitive and -resistant cases (50% lethal concentration <10th vs >90th percentile, n = 18), the binding motif for EBF1 was strikingly enriched in regions with differential open chromatin status (P = 8 × 10−174). CRISPR interference targeting EBF1 binding sites at the CD22 locus led to an ∼50-fold reduction in cell surface CD22 expression and, consequently, an ∼22-fold increase in InO resistance in ALL cell lines. Interestingly, within BCR::ABL1 ALL, we observed intrasubtype heterogeneity linked to EBF1 transcriptional downregulation (P = 1.1 × 10−15) and/or somatic alteration (P = .004), which led to reduced CD22 expression (P = 8.3 × 10−11) and ex vivo and in vivo resistance to InO. Collectively, these findings point to the direct impact of EBF1 on CD22 expression during B-cell development, which, in turn, contributes to interpatient variability in InO response, even within the same subtype of B-ALL.
A Proposal for HPV-Associated Oropharyngeal Carcinoma in the Ninth Edition Clinical TNM Classification
Huang, Shao Hui, Su, Jie , Koyfman, Shlomo A. , Hoebers, Frank , Bahig, Houda , Yu, Eugene , Bartlett, Eric , Davis, Robin L. , Woody, N.M. , Nelson, Kristoff , Lavigne, Danny , Nguyen‐Tan, Phuc Félix, Létourneau‐Guillon, Laurent , Filion, Édith, Nagelschneider, Alex A. , Abel, Kathryn M. Van , Postma, Alida A. , Palm, Walter M. , Lydiatt, William M. , Patel, Snehal G. , Routman, David, Van Abel, Kathryn M , Huang, Shao Hui, Routman, David M. , Spreafico, Anna , Lee, Jonathan Wei Jie , Stock, Sarah Jane , Daniel, J. , Hoeben, Ann , Chua, Melvin L.K. , Xu, Wei , O'Sullivan, Brian P

Mayo Clinic

JAMA Otolaryngology–Head & Neck Surgery | May 8, 2025 | Volume: 151 | Issue: 7 | Pages: 655

10.1001/jamaoto.2025.0848 | PMID 40338536 Get It

Importance A subset of Union for International Cancer Control ( UICC )/ American Joint Committee on Cancer ( AJCC ) eighth edition TNM stage I and II human papillomavirus–positive oropharyngeal carcinoma has undesirable outcomes, which might have contributed to a lack of success in phase III deintensification trials. Refining clinical stage groups, especially in the overabundant cN1/stage I group, has become important for treatment selection. Objective To assess the prognostic importance of pretreatment lymph node (LN) characteristics to optimize case distribution and outcome homogeneity within the N classification system. Design, Setting, and Participants This is an international multi-institutional retrospective prognostic cohort study. Analysis of human papillomavirus–positive oropharyngeal carcinoma treated curatively from 4 institutions (International Collaboration of Oropharyngeal Cancer Network for N-Classification [ICON-N] dataset) provided a refined clinical staging proposal; an independent dataset (Centre Hospitalier de l’Université de Montréal [CHUM] dataset) validated the proposal. Neuroradiologists reviewed pretreatment computed tomography and/or magnetic resonance imaging for nodal features, including presence or absence of abnormal LN(s), retropharyngeal LN, laterality, number of abnormal LN, and imaging-detected extranodal extension (iENE). Data were collected from February to May 2023, and data were analyzed from June to July 2023. Exposures Definitive chemoradiotherapy/radiotherapy or definitive surgery with or without postoperative chemoradiotherapy/radiotherapy. Main Outcomes and Measures The primary end point was overall survival. A Cox proportional hazards multivariable model was used to estimate adjusted hazard ratios (AHRs) and to derive an optimal clinical TNM stage classification (AHR-stage schema) incorporating the strongest prognostic nodal features within the UICC/AJCC eighth edition TNM framework after confirming the prognostication of iENE status. The performance (according to overall normalized scores and ranking) of the AHR-stage schema against the current UICC/AJCC eighth edition TNM staging system was evaluated for hazard consistency, hazard discrimination, prognostic importance, and sample size balance. Validation was performed in the CHUM dataset. Results The ICON-N dataset comprised 2053 patients, including 1898 (92.5%) with cN-positive disease and 155 (7.5%) with cN0 disease; a total of 298 (14.5%) were female, and the mean (SD) age was 60.6 (9.3) years. iENE-positive disease was identified in 710 of 1898 patients with cN-positive disease (37.4%). The median (range) follow-up was 5.1 (0.1-14.7) years. iENE was the strongest prognostic nodal feature in multivariable analysis; the AHR for iENE-positive vs iENE-positive disease was 2.43 (95% CI, 1.96-3.03) in the ICON-N dataset and 2.04 (95% CI, 1.28-3.23) in the CHUM dataset (n = 451). Reclassifying iENE-positive cases 1 stratum higher for N categorization without altering iENE-negative cases yielded an AHR-stage schema that outperformed the current TNM staging system in disease-free and overall survival with a lower (ie, better) overall normalized score (2 vs 3). Conclusions and Relevance In this study, reclassifying each N category 1 stratum higher for iENE-positive disease resulted in better disease-free and overall survival. The proposed new classification outperformed the currently TNM staging system in risk stratification and may facilitate future clinical trial design, outcomes research, and patient care.
Alemtuzumab in frontline therapy of adult acute lymphoblastic leukemia: Results of Cancer and Leukemia Group B 10102 (Alliance), a phase 1/2 study
Luskin, Marlise R. , Yin, Jun , Lozanski, Gerard , Curran, Emily , Malnassy, Gregory , Mrózek, Krzysztof , Bloomfield, C. D., Fulton, Noreen, Kolitz, Jonathan E. , LaPlant, Betsy, Kour, Oudom, Powell, Bayard L., Vij, Ravi , Grinblatt, David L. , Stone, Richard M. , Wang, Eunice S. , Larson, Richard A , Luskin, Marlise R , Cataland, Spero R. , Uy, Geoffrey L. , Larson, Richard A. , Stock, Wendy

Mayo Clinic

Cancer | February 7, 2025 | Volume: 131 | Issue: 4 | Pages: No page available

10.1002/cncr.35750 | PMID 39916320 Get It

AbstractBackgroundAcute lymphoblastic leukemia (ALL) in adults is aggressive, with long‐term outcomes impacted by treatment resistance and toxicity. CD52 is expressed in most cases of B‐ and T‐lineage ALL. Alemtuzumab, a humanized immunoglobulin G1 monoclonal antibody that targets CD52, was identified as a potential agent to improve treatment efficacy without increasing toxicity.MethodsIn this phase 1/2 study (Cancer and Leukemia Group B [CALGB] 10102, NCT00061945), a course of single‐agent alemtuzumab was intercalated into CALGB 19802 backbone chemotherapy after the third course of intensive chemotherapy in those who were CD52+ at diagnosis. Phase 1 tested three dose levels of subcutaneous alemtuzumab (10, 20, and 30 mg 3 times weekly for 4 weeks/12 doses) and demonstrated that 30 mg was tolerable. Phase 2 established feasibility.ResultsThe study enrolled 295 evaluable patients (115 in phase 1, 180 in phase 2); 206 (69.8%) were CD52+. Among evaluable CD52+ patients, 43.7% (90/206) completed the first three treatment modules; 97.8% (88 of 90) were treated with alemtuzumab. Alemtuzumab was associated with cytomegalovirus viremia, which occurred in 23.3% (14 of 60) of patients during and 29.2% (19 of 65) after alemtuzumab treatment. With a median follow‐up of 101.2 months, median overall survival (OS) was 26.3 months (3‐year rate, 44%; 5‐year rate, 36%; 10‐year rate, 31%). Landmark analysis at the start of the fourth course of treatment demonstrated no difference in OS or disease‐free survival between patients who did and who did not receive alemtuzumab.ConclusionAlemtuzumab was feasible to administer in adults with ALL receiving intensive chemotherapy, but was without evidence of benefit.
DNTT-mediated DNA damage response drives inotuzumab ozogamicin resistance in B-cell acute lymphoblastic leukemia
Escherich, Carolin S. , Hsiao, Yu-Chih , Yang, Wenjian , Li, Yizhen , Reyes, Noemi , Walker, Megan, Budhraja, Amit , Bhatara, Sheetal , Paietta, Elisabeth , Konopleva, Marina , Litzow, Mark R. , Inaba, Hiroto , Opferman, Joseph T. , Loh, Mignon L. , Yu, Jiyang , Evans, William E. , Li, Zhenhua , Yang, Wenjian , Li, Yizhen , Bhatara, Sheetal , Konopleva, Marina , Litzow, Mark R. , Pui, Ching-Hon , Loh, Mignon L , Yu, Jiyang , Yang, Jun J.J. , Inaba, Hiroto , Escherich, Carolin , Moriyama, Takaya , Li, Zhenhua, Díaz-Flores, Ernesto , Stock, Wendy , Kornblau, Steven M. , O'Brien, Maureen Megan

Mayo Clinic

Blood | January 10, 2025 | Volume: 145 | Issue: 11 | Pages: 1182-1194

10.1182/blood.2024026085 | PMID 39791601 Get It

Abstract Inotuzumab ozogamicin (InO) is an antibody-calicheamicin conjugate with striking efficacy in B-cell acute lymphoblastic leukemia (B-ALL). However, there is wide interpatient variability in treatment response, and the genetic basis of this variation remains largely unknown. Using a genome-wide CRISPR screen, we discovered that the loss of DNA nucleotidylexotransferase (DNTT) is a primary driver of InO resistance. Mechanistically, the downregulation of DNTT attenuated InO–induced DNA damage response, cell cycle arrest, and mitochondrial apoptotic priming, thereby ultimately leading to leukemia resistance to InO. Ex vivo leukemia InO sensitivity was highly associated with DNTT expression in ALL blasts with substantial intraleukemia heterogeneity as revealed by single-cell RNA sequencing. Among patients with B-ALL enrolled in the Children's Oncology Group trial AALL1621, we observed consistent DNTT downregulation in residual blasts following InO treatment. The selection of DNTT-low blasts by InO therapy was also recapitulated in vivo using patient-derived xenograft models. Collectively, our data indicate that DNTT is a key regulator of calicheamicin response in leukemia and thus a potential biomarker for individualizing InO therapy in B-ALL.
Outcomes and Survival in Newly Diagnosed, Older, Acute Myeloid Leukemia Patients from the Beat AML Master Trial in the Venetoclax/Azacitidine Age
Borate, Uma , Huang, Ying , Swords, Ronan , Stein, Eytan M. , Patel, Prapti A. , Collins, Robert H. , Baer, Maria R. , Blum, William , Arellano, Martha , Odenike, Olatoyosi , Redner, Robert L. , Kovacsovics, Tibor , Deininger, Michael W. , Olin, Rebecca L. , Foran, James M. , Schiller, Gary J. , Curran, Emily , Koenig, Kristin L , Heerema, Nyla A. , Martycz, Molly , Stefanos, Mona , Marcus, Sonja, Rosenberg, Leonard, Burd, Amy , Yocum, Ashley O. , Byrd, John C. , Byrd, John C. , Byrd, John C , Welkie, Rina Li , Traer, Elie , Lin, Tara L. , Madanat, Yazan F. , Duong, Vu H. , Stock, Wendy , Zeidner, Joshua F. , Smith, Catherine C. , Chen, Timothy Frank , Druker, Brian J , Levine, Ross L. , Mims, Alice S

Mayo Clinic

Blood | December 6, 2024 | Volume: 144 | Issue: Supplement 1 | Pages: 4324-4324

10.1182/blood-2024-211178 Get It

Background: The BeatAML Master Trial (BAMT) began in 2016 with a goal of determining the feasibility of a precision-medicine approach in treating acute myeloid leukemia (AML) in older adults ≥ 60 years of age where outcomes are poor. At the time, standard of care (SOC) for older patients with AML was intensive 7+3 chemotherapy (cytarabine + daunorubicin) if fit and hypomethylating agents (HMA: azacitidine or decitabine) if unfit. Besides confirming the feasibility, the early results (2019) from the Master Trial suggested that patients who received therapy on one of the sub-studies had a lower early death rate and superior overall survival compared to patients receiving off-protocol SOC, which was primarily single-agent HMA at the time. Since then, the 2019 approval of venetoclax (ven) + azacitidine for older unfit AML patients has been transformative and emerged as the SOC. Using data from the BAMT from 2016-2024, we suggest that knowing the comprehensive genomic profile of AML at the time of diagnosis is still beneficial in determining therapy that would lead to the optimal outcome and that development of targeted therapies and combination regimens with ven/HMA is still needed. Methods: This is a retrospective analysis of 1096 patients who consented and enrolled on the BAMT (NCT03013998) from Nov 2016 through Jun 2024. Patients ≥ 60 years with newly diagnosed AML were included. Patients underwent therapy on a BeatAML sub-study based on their genetics (N=433) or treatment off-protocol (N=663). We divided the patients according to what therapy they received: (1) Non-Intensive (Off-Protocol, N=121), (2) Ven/HMA (Off-Protocol, N=234), (3) Non-Intensive (Sub-Study, N=407), (4) Intensive (Sub-Study, N=26), and (5) Intensive (Off-Protocol, N=155). 94 patients received no treatment and 59 were unknown. Non-intensive therapies included primarily targeted agents or non-ven combinations. We analyzed baseline characteristics and demographics, overall survival (OS), and the impact of allogenic stem cell transplant (SCT). OS, using Kaplan-Meier method, was measured from the start of therapy to all-cause death, censoring patients at last follow-up. Results: Characteristics and demographics were similar between Groups 1, 2 and 3. Group 4 and 5 were treated with intensive chemotherapy and their characteristics are reflective of younger/fit patients appropriate for the intensive regimen. Groups 4 and 5 also had the longest median OS (mOS) of 40.2 months (95% CI: 13.9-not reached (NR)) and 42.3 months (95% CI: 25.1-NR) respectively. Group 3, which included patients treated with a non-intensive, targeted therapy on a sub-study, had an mOS of 14.0 months (95% CI: 12.3-16.7), which was similar to Group 2, treated with Ven/HMA, that had an mOS of 13.2 months (95% CI: 10.9-16.3). Lastly, patients in Group 1, who were treated primarily with HMA monotherapy, did poorly in comparison, with an mOS of 6.0 months (95% CI: 3.3-10.1). Additionally, we looked at the cumulative incidence rate (CIR) of SCT. The CIR in 12 months of Group 1 was 9.8% (95% CI: 6.9-13.4), Group 2: 5.4% (95% CI: 2.2-10.7), Group 3 and 4 combined: 35.0% (95% CI: 628.1-42.1), and Group 5: 13.1% (95% CI: 6.9-13.4). In a multi-variable analysis, after adjusting for typical favorable risk factors like NPM1 mutations and core binding factor, SCT was highly significant (p<0.0001) in improving OS with a hazard ratio of 0.23 (95% CI: 0.16-0.32), and Group 3 performed similarly to Group 2 (p=0.20). Conclusions: First, our results suggest that it is clinically relevant to correctly identify whether an intensive chemotherapy, targeted-therapy, or ven/HMA regimen is best suited for older AML patients, for which a precision-medicine trial is ideal for. Secondly, in this group of patients, our results show that patients treated with a non-intensive targeted therapy (Group 3) has a similar mOS to those treated with ven/HMA (Group 2). Especially after controlling for patient characteristics, patients in Group 2 performed similar to those in Group 3 (p=0.20). Patients in Group 3 were treated on Beat AML sub-studies which included targeted therapy alone or with non-venetoclax combinations, which is a strong rationale for continued development of targeted agents to optimize toxicity and quality of life with similar survival. Lastly, this data also supports the need to improve the ven/HMA SOC by developing combination regimens with targeted agents to further improve outcomes.